Neisseria Gonorrhoeae RNA Test · Urine

Most gonorrhea infections cause no symptoms at all. Between 86.4 and 92.6 percent of urogenital infections in women, and 55.7 to 86.8 percent in men, are completely silent, which means the only way to know you have one is to test for it.

This test looks for genetic material from Neisseria gonorrhoeae, the bacterium behind gonorrhea, in a urine sample. A positive result signals an active infection that needs antibiotics. Untreated, the bacterium can scar fallopian tubes, trigger pelvic inflammatory disease, and in rare cases spread into the joints, skin, and bloodstream.

What This Test Actually Measures

The lab uses a technique called a nucleic acid amplification test (NAAT), which makes millions of copies of any Neisseria gonorrhoeae genetic sequences in your sample so they can be detected. Unlike cholesterol or blood sugar, this is not a number on a sliding scale. The result is either positive (the bacterium is there) or negative (it is not detected in this sample).

The test performs well. Modern NAATs have sensitivity above 90 percent (they catch more than 90 out of 100 true infections) and specificity of 97 percent or higher (they correctly rule out more than 97 out of 100 uninfected people). That beats older culture-based methods, which catch only 50 to 85 percent of infections and miss even more at throat and rectal sites.

Why Silent Infections Matter

Gonorrhea does not wait for symptoms to do damage. In women, an untreated urogenital infection can climb into the uterus and fallopian tubes, causing pelvic inflammatory disease (PID). PID leaves behind scar tissue that can block tubes, leading to infertility or pregnancies that implant outside the uterus (ectopic pregnancies), which are medical emergencies.

In a smaller number of people (about 0.5 to 3 percent of untreated infections), the bacterium escapes the initial infection site and spreads through the bloodstream. This is called disseminated gonococcal infection. It shows up as skin lesions, joint pain, and inflamed tendons, and most cases involve septic arthritis in one or more joints. Rarer complications include infection of the heart valves, the lining around the brain, and the tissue around the liver.

Cancer Associations

A history of gonorrhea infection has been linked to higher prostate cancer risk in several studies, though the relationship is not fully understood. A meta-analysis pooling 47 studies found men with any prior sexually transmitted infection had roughly 1.5 times higher prostate cancer risk, with gonorrhea specifically showing a smaller but still elevated risk (summary relative risk 1.20, 95 percent confidence interval 1.05 to 1.37). A Taiwanese population-based cohort study reported a stronger link (adjusted hazard ratio 5.66, 95 percent confidence interval 1.36 to 23.52) after accounting for age, other health conditions, urbanization, and income, though that analysis included only 355 men with gonorrhea and had wide uncertainty bounds.

These studies cannot prove gonorrhea causes prostate cancer. The association may reflect shared risk factors or co-infection with other organisms. Still, it is a reason to treat every gonorrhea infection promptly rather than hoping it clears on its own.

How to Interpret Your Result

The biggest confounder for this test is not diet or medication. It is whether you are being tested at a site where your sample type is validated. Urine is the preferred specimen for men and works well for urogenital infections. It is not designed to detect infections in the throat or rectum, which require swabs of those sites.

Among men who have sex with men, 14 to 85 percent of gonorrhea infections are found only at the throat or rectum. Urine-only screening misses most infections in this group. If you have had oral or receptive anal sex, a negative urine result does not rule out gonorrhea at those other sites.

Positive results in low-risk populations need a second look. When overall infection rates in a group are very low (for example, 0.4 percent in a general survey), even a highly accurate test produces many false alarms. In that setting, only about 19 percent of initial positive results represented true infections. This is why guidelines recommend confirmatory testing with a second NAAT that targets a different bacterial gene, especially for throat samples and in people without risk factors.

Reference Ranges and Result Interpretation

Because this test is binary rather than a numeric value, there is no optimal range to aim for. The only acceptable result is "not detected."

Different labs use different NAAT platforms (Aptima, Alinity, GeneXpert, Roche cobas, and others), and each targets different bacterial genetic sequences. Cross-reactivity with harmless Neisseria species varies by platform. If you get an unexpected positive, ask which platform your lab uses and whether a confirmatory test with a different target was run.

Why Retesting Matters

A single negative test covers a single moment and a single site. Gonorrhea can be picked up from any new sexual encounter, and an infection acquired today will not necessarily be detectable tomorrow. For people with ongoing exposure risk, guidelines recommend at least annual testing, and every 3 to 6 months for higher-risk individuals such as men who have sex with men with multiple partners or anyone with new or anonymous partners.

Serial testing also matters after treatment. A test-of-cure 7 to 14 days later is recommended for throat infections because ceftriaxone (the first-line antibiotic) is less reliable there than at urogenital sites. Modeling studies in men who have sex with men suggest that quarterly screening, compared to annual, could substantially reduce new infection rates at the population level by catching asymptomatic carriers before they transmit to partners.

When Results Can Be Misleading

Several situations can produce a false positive or a misleading negative. The main ones cluster into three groups.

• Cross-reactivity with harmless bacteria: Commensal Neisseria species that normally live in the throat can carry genetic sequences similar to those of N. gonorrhoeae. This is mainly a problem for throat samples, and different test platforms have different rates of this error. A 2025 study identified a novel commensal species that caused false positives on Roche cobas platforms but not on Aptima.
• Low-prevalence false positives: If you have no risk factors and come from a low-prevalence group, a single positive has a substantial chance of being wrong. Confirmatory testing with a second gene target is standard in this situation.
• Recent antibiotics: Antibiotic treatment for another condition can lower bacterial load and produce a false negative, though residual genetic material may still be detectable for a short time after treatment.
• Urine collection timing: For first-catch urine samples, holding urine for at least 1 hour before collection improves sensitivity. A heavily diluted sample from frequent urination can miss a low-level infection.